My ePortfolio Register   

Adaptive trial design on breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.05.17
Views: 696
Rating:

Prof Laura Vant Veer - University of California San Francisco, San Francisco, USA

Prof Veer speaks with ecancer at IMPAKT 2017 about breast cancer characteristics and treatment selection.

She describes 'getting under the hood' of tumour gene expression, which led to the identification of 70 genes which can inform a patient's risk of cancer recurrence, and their suitability for further chemotherapy.

Prof Veer places emphasis on collaboration and education amongst clinicians as a means to develop trial design and protocol, with the goal of bringing the benefits of targeted therapy to a wider patient base.

Mammaprint was discussed at AACR 2016 by Dr Martine Piccart, here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence